MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.
Peterfy, Charles; Emery, Paul; Tak, Paul P; Østergaard, Mikkel; DiCarlo, Julie; Otsa, Kati; Navarro Sarabia, Federico; Pavelka, Karel; Bagnard, Marie-Agnes; Gylvin, Lykke Hinsch; Bernasconi, Corrado; Gabriele, Annarita.
Ann Rheum Dis
; 75(1): 170-7, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25355728
A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico.
Rituximab for rheumatoid arthritis.
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis.
Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment.
Anterior ST-elevation myocardial infarction induced by rituximab infusion: A case report and review of the literature.
Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.